Post-earnings recap
Reported
Thu, Jul 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bio-Rad's strong EPS performance indicates better-than-expected profitability, which likely contributed to the 2.41% increase in stock price. The company is navigating supply chain challenges while focusing on growth and innovation. Investors may view this as a positive sign for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.38 | N/A | +37.40% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a positive outlook despite external challenges. They emphasized their commitment to innovation and customer satisfaction.
Management highlighted strong performance in key segments.
They noted ongoing challenges in the supply chain but remain focused on growth.